Royal Peptides LLC
Has Royal Peptides LLC received an FDA warning letter? Yes. FDA issued a warning letter dated August 24, 2026 concerning products containing tirzepatide and semaglutide and retatrutide.
Letter facts
- Letter date
- August 24, 2026 (2026-08-24)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Products named
- TirzepatideSemaglutideRetatrutideSS-31 (Elamipretide)PT-141TesamorelinBIMORELIN
- Violation categories
- Unapproved new drugMisbranding
Understanding these violation categories
Unapproved new drug
FDA says these products have not been reviewed or approved for safety and effectiveness before being marketed. A warning letter gives the company an opportunity to address the violations.
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
Factual Violation Summary
FDA says the website review found Tirzepatide, Semaglutide, Retatrutide, SS-31, PT-141, Tesamorelin, and BIMORELIN marketed as unapproved new drugs with drug-intended labeling; introducing them into interstate commerce violates FD&C Act sections 301(d) and 505(a).
Active Drug Ingredients
Statutory Citations & Specific Allegations
- Unapproved New Drug Violations
More letters about Retatrutide
Recent FDA warning letters concerning Retatrutide:
- Tex PeptidesAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
- Peptide Partners LLCAugust 24, 2026
- Peak Performance PeptidesAugust 24, 2026
- Prime SciencesMarch 31, 2026
Similar violations (Unapproved new drug)
Recent warning letters with related regulatory findings:
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
- NuScience Peptides LLCAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.